Aralez Pharma, Anchored In Cardiovascular, Will Be Prowling For Assets
This article was originally published in The Pink Sheet Daily
The new company, to be formed through the merger of Pozen and Tribute, will develop a commercial organization to sell Yosprala and look to bring in new assets through licensing and M&A.
You may also be interested in...
Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.
If the aspirin/omeprazole finally gets approved on its third FDA review, Aralez then will face the challenge of positioning a prescription product against generic, over-the counter versions of both of its main components.
The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.